NASDAQ:CVRX CVRx (CVRX) Stock Price, News & Analysis → Fidelity, Bezos, Goldman Bet Big on Tiny Biotech (From Behind the Markets) (Ad) Free CVRX Stock Alerts $7.79 -0.31 (-3.83%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$7.72▼$8.1750-Day Range$7.97▼$21.8752-Week Range$7.71▼$33.13Volume407,172 shsAverage Volume186,247 shsMarket Capitalization$168.19 millionP/E RatioN/ADividend YieldN/APrice Target$16.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get CVRx alerts: Email Address CVRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside113.1% Upside$16.60 Price TargetShort InterestHealthy8.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.10Based on 18 Articles This WeekInsider TradingSelling Shares$151,903 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.39) to ($1.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.56 out of 5 starsMedical Sector261st out of 905 stocksSurgical & Medical Instruments Industry35th out of 95 stocks 4.3 Analyst's Opinion Consensus RatingCVRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCVRx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CVRx's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.45% of the float of CVRx has been sold short.Short Interest Ratio / Days to CoverCVRx has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in CVRx has recently decreased by 5.33%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCVRx does not currently pay a dividend.Dividend GrowthCVRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CVRX. Previous Next 2.2 News and Social Media Coverage News SentimentCVRx has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for CVRx this week, compared to 3 articles on an average week.Search Interest9 people have searched for CVRX on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows4 people have added CVRx to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CVRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $151,903.00 in company stock.Percentage Held by Insiders18.90% of the stock of CVRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.27% of the stock of CVRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CVRx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CVRx are expected to grow in the coming year, from ($2.39) to ($1.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CVRx is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CVRx is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCVRx has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CVRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCould this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.Access my full "Cut & Paste" profit analysis now. About CVRx Stock (NASDAQ:CVRX)CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Read More CVRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVRX Stock News HeadlinesMay 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRXMay 4, 2024 | americanbankingnews.comCraig Hallum Begins Coverage on CVRx (NASDAQ:CVRX)May 8, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.May 4, 2024 | americanbankingnews.comPiper Sandler Cuts CVRx (NASDAQ:CVRX) Price Target to $15.00May 4, 2024 | americanbankingnews.comWilliam Blair Research Analysts Decrease Earnings Estimates for CVRx, Inc. (NASDAQ:CVRX)May 4, 2024 | americanbankingnews.comCVRx, Inc. (NASDAQ:CVRX) Receives $19.40 Average PT from BrokeragesMay 3, 2024 | finance.yahoo.comCVRx, Inc. (NASDAQ:CVRX) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMay 3, 2024 | americanbankingnews.comCVRx (NASDAQ:CVRX) Stock Rating Lowered by William BlairMay 8, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.May 3, 2024 | americanbankingnews.comJPMorgan Chase & Co. Downgrades CVRx (NASDAQ:CVRX) to NeutralMay 3, 2024 | americanbankingnews.comCVRx (NASDAQ:CVRX) PT Lowered to $14.00May 2, 2024 | msn.comCVRx stock plunges 42% in wake of Q1 report, updated forecastMay 2, 2024 | msn.comWilliam Blair Downgrades CVRx (CVRX)May 2, 2024 | finance.yahoo.comCVRx First Quarter 2024 Earnings: Misses ExpectationsMay 2, 2024 | americanbankingnews.comCVRx (NASDAQ:CVRX) Given New $18.00 Price Target at Lake Street CapitalMay 2, 2024 | americanbankingnews.comCVRx, Inc. (NASDAQ:CVRX) Short Interest UpdateMay 1, 2024 | finance.yahoo.comCVRx, Inc. (NASDAQ:CVRX) Q1 2024 Earnings Call TranscriptMay 1, 2024 | markets.businessinsider.comCVRX Stock Earnings: CVRx Misses EPS, Misses Revenue for Q1 2024May 1, 2024 | benzinga.comUS Stocks Mixed; Amazon Posts Upbeat EarningsMay 1, 2024 | finance.yahoo.comCVRx Inc (CVRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and Setting ...May 1, 2024 | finance.yahoo.comQ1 2024 CVRx Inc Earnings CallMay 1, 2024 | investorplace.comWhy Is CVRx (CVRX) Stock Down 32% Today?April 30, 2024 | marketwatch.comStocks to Watch: Pinterest, Root, Clorox, Denny's, CVRxApril 30, 2024 | marketwatch.comCVRx Shares Tumble 26% After Execution Issues Dent RevenueApril 30, 2024 | finance.yahoo.comCVRx Reports First Quarter 2024 Financial and Operating ResultsApril 30, 2024 | finance.yahoo.comCVRx Inc (CVRX) Reports Q1 2024 Results: Revenue Growth Amid ChallengesApril 28, 2024 | americanbankingnews.comCVRx (CVRX) Set to Announce Quarterly Earnings on TuesdaySee More Headlines Receive CVRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CVRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today5/08/2024Next Earnings (Estimated)7/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:CVRX CUSIPN/A CIK1235912 Webwww.cvrx.com Phone763-416-2840Fax763-416-2841Employees200Year FoundedN/APrice Target and Rating Average Stock Price Target$16.60 High Stock Price Target$23.00 Low Stock Price Target$13.00 Potential Upside/Downside+113.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,200,000.00 Net Margins-123.58% Pretax Margin-104.47% Return on Equity-62.73% Return on Assets-46.35% Debt Debt-to-Equity Ratio0.38 Current Ratio14.25 Quick Ratio12.86 Sales & Book Value Annual Sales$39.29 million Price / Sales4.28 Cash FlowN/A Price / Cash FlowN/A Book Value$3.65 per share Price / Book2.13Miscellaneous Outstanding Shares21,590,000Free Float17,514,000Market Cap$168.19 million OptionableOptionable Beta1.35 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Kevin Hykes (Age 58)President, CEO & Director Mr. Jared Oasheim (Age 40)Chief Financial Officer Comp: $446.1kMr. Paul Verrastro (Age 61)Chief Marketing & Strategy Officer Comp: $529.84kMr. Paul PignatoVice President of OperationsMs. Jonelle R. Burnham (Age 53)Vice President & General Counsel Mr. Craig Palmer (Age 47)Senior Vice President of US Sales More ExecutivesKey CompetitorsAccurayNASDAQ:ARAYOrchestra BioMedNASDAQ:OBIOQuipt Home MedicalNASDAQ:QIPTAlpha Tau MedicalNASDAQ:DRTSProfound MedicalNASDAQ:PROFView All CompetitorsInsiders & InstitutionsValeo Financial Advisors LLCBought 19,000 shares on 4/25/2024Ownership: 0.088%GSG Advisors LLCSold 125,500 shares on 4/11/2024Ownership: 0.167%Paul VerrastroSold 2,545 sharesTotal: $55,760.95 ($21.91/share)& Johnson JohnsonSold 3,725 sharesTotal: $96,142.25 ($25.81/share)Parkman Healthcare Partners LLCBought 17,880 shares on 2/15/2024Ownership: 1.147%View All Insider TransactionsView All Institutional Transactions CVRX Stock Analysis - Frequently Asked Questions Should I buy or sell CVRx stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CVRx in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CVRX shares. View CVRX analyst ratings or view top-rated stocks. What is CVRx's stock price target for 2024? 6 Wall Street research analysts have issued 12 month target prices for CVRx's stock. Their CVRX share price targets range from $13.00 to $23.00. On average, they expect the company's stock price to reach $16.60 in the next twelve months. This suggests a possible upside of 113.1% from the stock's current price. View analysts price targets for CVRX or view top-rated stocks among Wall Street analysts. How have CVRX shares performed in 2024? CVRx's stock was trading at $31.44 at the beginning of 2024. Since then, CVRX stock has decreased by 75.2% and is now trading at $7.79. View the best growth stocks for 2024 here. Are investors shorting CVRx? CVRx saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 786,500 shares, a decline of 5.3% from the March 31st total of 830,800 shares. Based on an average daily volume of 142,000 shares, the short-interest ratio is currently 5.5 days. Approximately 8.5% of the shares of the company are sold short. View CVRx's Short Interest. When is CVRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 23rd 2024. View our CVRX earnings forecast. How were CVRx's earnings last quarter? CVRx, Inc. (NASDAQ:CVRX) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.08. The business earned $3.40 million during the quarter, compared to the consensus estimate of $3.42 million. CVRx had a negative net margin of 123.58% and a negative trailing twelve-month return on equity of 62.73%. What ETF holds CVRx's stock? iShares Neuroscience and Healthcare ETF holds 717 shares of CVRX stock, representing 0.32% of its portfolio. What guidance has CVRx issued on next quarter's earnings? CVRx issued an update on its second quarter 2024 earnings guidance on Tuesday, April, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11.3 million-$12.3 million, compared to the consensus revenue estimate of $13.1 million. When did CVRx IPO? CVRx (CVRX) raised $100 million in an IPO on Wednesday, June 30th 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share. Who are CVRx's major shareholders? CVRx's stock is owned by a variety of institutional and retail investors. Top institutional investors include GSG Advisors LLC (0.17%), Valeo Financial Advisors LLC (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include & Johnson Johnson, Kirk G Nielsen, Mudit K Jain, Nea Partners 10 L P and Paul Verrastro. View institutional ownership trends. How do I buy shares of CVRx? Shares of CVRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CVRX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CVRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
